Canexia Health’s Find It panel detects mutations in DNA from solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.
Find It and Fusions are amplicon-based NGS panels for the detection of SNVs, CNVs, MSI status, and gene fusions in solid tumor tissue. Genomic aberrations, such as those assessed by the Find It and Fusions panels, are highly variable across tumors, with any single tumor having its own unique collection of genomic changes. Utilizing targeted multigene panels, such as the Find It and Fusions assays, allows for quick, cost-effective, and simplified methods for detecting a tumor’s unique mutational signature. These unique signatures can then be used to help tailor treatments, predict cancer prognosis, or determine eligibility for clinical trials based on specific mutations detected.
To provide the most valuable information on tissue mutation signatures, Canexia Health’s Find It and Fusions assays focus on genomic content that is associated with approved targeted therapies, those in late stage clinical trials, or are known to provide key prognosis or treatment resistance information for common solid tumors cancers such as non-small cell lung, breast, colorectal, endometrial, melanoma, GIST, gliomas, and sarcoma.